Indications & Stages

  • RESEARCH
  • PRECLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA

Soft Tissue Sarcoma*
CE MARK
Head & Neck Cancer (RTx alone)**
PHASE I/II TRIAL DONE
Liver Cancer (RTx alone)**
PHASE I/II TRIAL ONGOING
Prostate Cancer (RTx alone)**
PHASE I/II TRIAL ONGOING
Head & Neck Cancer (RTx + chemo)
PHASE I/II TRIAL ONGOING
Rectal Cancer (RTx + chemo)
PHASE I/II TRIAL ONGOING
H&N & Lung Cancer (RTx + anti-PD-1/PD-L1)**
PHASE I TRIAL ONGOING

References

NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY (NAPOLI-1): A GLOBAL, RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Lancet. 2016; 387: 545-57

MANAGEMENT OF METASTATIC PANCREATIC CANCER: CURRENT TREATMENT OPTIONS AND POTENTIAL NEW THERAPEUTIC TARGETS

Sclafani F, Iyer R, Cunningham D, Starling N; Crit Rev Oncol Hematol. 2015; 95: 318-36

CANCER OF THE PANCREAS: ESMO CLINICAL PRACTICE GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere? D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; Ann Oncol. 2015; 26 Suppl 5: v56-68

PHASE I STUDY OF NANOLIPOSOMAL IRINOTECAN (PEP02) IN ADVANCED SOLID TUMOR PATIENTS

Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT; Cancer Chemother Pharmacol 2015; 75: 579–86

A MULTINATIONAL PHASE II STUDY OF LIPOSOME IRINOTECAN (PEP02) FOR PATIENTS WITH GEMCITABINE-REFRACTORY METASTATIC PANCREATIC CANCER

A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, G. Yeh, L. Chen; Br J Cancer 2013; 109: 920–25

A RANDOMIZED PHASE II STUDY OF PEP02 (MM-398), IRINOTECAN OR DOCETAXEL AS A SECOND-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A; Ann Oncol. 2013; 24: 1567–73

CONVECTION-ENHANCED DELIVERY OF NANOLIPOSOMAL CPT-11 (IRINOTECAN) AND PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL) IN RODENT INTRACRANIAL BRAIN TUMOR XENOGRAFTS

Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS; Neuro Oncol. 2007; 9:393403

PHASE I STUDY OF NBTXR3 NANOPARTICLES, IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS)

S. Bonvalot, C.L. Pechoux, T.D. Baere, et al; J Clin Oncol 32:5s, 2014 (suppl; abstr10563)

NEW USE OF METALS AS NANOSIZED RADIOENHANCERS

Pottier A, Borghi E, Levy L; Anticancer Res. 2014 Jan;34(1):443-53. Review

HAFNIUM OXIDE NANOPARTICLES: TOWARD AN IN VITRO PREDICTIVE BIOLOGICAL EFFECT?

Marill J, Anesary NM, Zhang P, Vivet S, Borghi E, Levy L, Pottier A; Radiat Oncol. 2014 Jun 30;9:150

FIRST-IN-HUMAN STUDY TESTING A NEW RADIOENHANCER USING NANOPARTICLES (NBTXR3) ACTIVATED BY RADIATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMAS

Bonvalot S, Le Pechoux C, De Baere T, et al; Clin Cancer Res. 2017 Feb 15;23(4):908-917

PACKAGE LEAFLET

BACK TO R & D PIPELINE
Go To Top